The National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract to Camris International, LLC to support biomedical research programs. The contract vehicle has a potential value of $545,452,906 to be obligated against through task orders over a seven-year ordering period ending August 2028. Two task orders have been awarded to date under the contract: one for $545,232 for current good manufacturing practice process development of a trachoma vaccine in Bethesda,...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract to PPD Development LP with a potential value of $545,452,906 to provide comprehensive and rapid response capabilities for research programs through September 2028. Task orders issued against the contract include over $132 million for clinical trial management support services relating to COVID-19, as well as orders valued at $2.33 million, $2 million, and $82.5...
This indefinite delivery contract was awarded by the Office of the Director, a civilian federal agency, to Charles River Laboratories, Inc., a for-profit global contract research organization. The contract, valued at up to $98.8 million, provides a multiple award vehicle for Charles River to deliver a range of essential products and services to support the agency's biomedical research and development efforts. This likely includes supplying laboratory animals, diagnostic testing, virus...
The National Institute of Allergy and Infectious Diseases awarded an indefinite delivery contract to FHI Clinical Inc. to provide comprehensive and rapid response research programs. The contract has a potential value of $545,452,906 over a seven-year ordering period through August 2028. Two task orders have been issued against it to date, one for $332,178 and another for $2,000. Under the contract, FHI Clinical Inc. will support the NIAID's mission to conduct biomedical research on infectious,...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, awarded a single-award Indefinite Delivery Contract valued up to $146,300,000 to Southern Research Institute, a non-profit research organization, to develop and employ animal and animal replacement models of infectious diseases. The contract will support screening, product evaluation, and eventual clinical evaluation of vaccines, therapeutics, and...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a multiple-award Indefinite Delivery Contract (IDC) worth up to $80 million to the International AIDS Vaccine Initiative (IAVI), a global non-profit organization. Under this IDC, IAVI provides a range of research, development, manufacturing, and advocacy services to advance the creation and delivery of vaccines and antibodies for infectious diseases such as HIV,...
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to The Charles Stark Draper Laboratory, Inc. (Draper) for the development and employment of animal and animal replacement models of infectious diseases. The $146.3 million single-award IDC has a 7-year ordering period and supports the full range of preclinical evaluations, including screening, product evaluation, and eventual clinical evaluation of...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract to Lovelace Biomedical Research Institute on September 1, 2021 with a potential value of $545,452,906. Under the terms of the contract, Lovelace Biomedical Research Institute will provide a broad range of services to support biomedical research conducted by NIAID, including clinical trials, manufacturing and controls, nonclinical animal studies, analytics,...
This single-award Indefinite Delivery Contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to Battelle Memorial Institute, a non-profit organization and manufacturer of goods, to provide pre-clinical models of infectious diseases. The $146.3 million, 7-year contract has a completion date of July 14, 2031 and was awarded on July 15, 2024. The contract aims to develop and employ animal and...
This indefinite delivery contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. federal government, aims to provide the capability and capacity to develop and employ animal and animal replacement models of infectious diseases for screening, product evaluation, and eventual clinical evaluation. The single-award contract, with a 7-year ordering period and a ceiling value of $146.3 million, was awarded to Sigmovir Biosystems, Inc., a...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award Indefinite Delivery Contract to Charles River Laboratories, Inc. to provide clinical trial materials for virus vaccines with a maximum ordering value of $24,519,468.00 over a seven year period from February 2021 through February 2028. Under this contract vehicle, the agency has issued multiple firm fixed price delivery orders to Charles River for services including the production of virus cell banks, clinical trial materials, challenge viruses, and vaccine candidates for diseases such as influenza, respiratory syncytial virus, dengue, West Nile virus, Ebola, Zika, coronaviruses, and others. Delivery orders have been awarded with values ranging from approximately $76,000 to $1,375,000 and periods of performance from 6 months to 2 years to support vaccine research and development efforts. Charles River will perform associated manufacturing and testing activities at its location in Wilmington, Massachusetts. The original solicitation sought a cGMP compliant contract manufacturing organization to rapidly produce vaccine candidates and ancillary products for clinical trials as needed to advance the National Institute of Allergy and Infectious Diseases' mission of developing effective countermeasures for human infectious diseases.